فاینەستراید

فاینەستراید (بە ئینگلیزی: Finasteride) بەتەنھا و لەژێر ناوی بازرگانی پرۆسکار و پرۆپێشیا دەفرۆشێرێت، لەنێوان دەرمانەکانی تر، ئەم دەرمانە بەکاردێت بۆ چارەسەری گەورەبوونی پرۆستات یان کەم بوون و لەدەست دانی قژ لە ڕەگەزی نێردا^[١] ھەروەھا ئەتوانرێ بۆ چارەسەری زۆری موو بەکاربێت لە ڕەگەزی مێ دا، و وەک بەشێک لە چارەسەری ھۆرمۆنی بۆ ترانسجێندەر بەکاردێت^[٢]^[٣] و لە ڕێگەی دەمەوە وەردەگیرێ^[١]

فاینەستراید (وەستێنەر یان خاوکەرەوە) ی ئەنزیمی (5α-Reductase) کە دژە ئەندرۆجینە^[٤] کاردەکات بە کەمکردنەوەی ڕێژەی دیھایدرۆتێستۆستیرۆن (DHT) بە نزیکەیی ڕێژەی %٧٠، لەناویاندا لە پرۆستات و لەناو سەر^[١]

کاریگەرییە لاوەکییەکان لە بەکارھێنانی فاینەستراید دەگەمەنن^[٥]ھەرچۆنێک بێت لە ڕەگەزی نێر ھەنێک کەس ھەست (لاوازی ئارەزووی سێکس، خەمۆکی، گەورەبوونی مەمکەکان) دەکەن لە ھەنێک لە ڕەگەزی نێردا^[٦]^[٧]لەھەنێک کەسدا لەوانەیە لاوازی سێکس بەردەوام بێت دوای واز ھێنانیش لە دەرمانەکە^[٨]^[٩]لەوانەیە ھەنێک لە نیشانە سەرەتایەکان لە چەن بەشێکی سەرەکی شێرپەنجەی پرۆستات بشارێتەوە^[١٠]

فاینەستراید لە ساڵی ١٩٨٤ دا خرایە ڕوو و لە ١٩٩٢ دا وەک دەرمان پەسەند کرا^[١١]

بەکارھێنانە پزیشکییەکان[دەستکاری]

فاینەستراید بۆ چارەسەری حالەتی (prostatic hyperplasia) بەکاردێت، لە ڕەگەزی نێردا بۆ چارەسەری گەورە بوونی پرۆستات^[١٢] و بۆ چارەسەری لەدەست دانی قژ و ھەڵوەرینی قژ لە ڕەگەزی نێردا بەکاردێت (androgenetic alopecia)^[١٣]

کارلێک لەگەل دەرمانی تر[دەستکاری]

لەوانەیە ئێستا ھیچ داتەیەک بەردەست نەبێت لەوەی فاینەستراید کارلێک بکات لەگەل ھیچ دەرمانێک^[١٤]

سەرچاوەکان[دەستکاری]

^ ^ئ ^ا ^ب "Finasteride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 5 March 2019.
^ Blume-Peytavi, Ulrike; Whiting, David A.; Trüeb, Ralph M. (26 June 2008). Hair Growth and Disorders. Springer Science & Business Media. p. 369. ISBN 978-3-540-46911-7.
^ Knezevich EL, Viereck LK, Drincic AT (January 2012). "Medical management of adult transsexual persons". Pharmacotherapy. 32 (1): 54–66. doi:10.1002/PHAR.1006. PMID 22392828. S2CID 12853220.
^ Ferri, Fred F. (2014). Ferri's Clinical Advisor 2015 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 580. ISBN 978-0-323-08430-7.
^ Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ (October 2010). "Finasteride for benign prostatic hyperplasia". The Cochrane Database of Systematic Reviews (10): CD006015. doi:10.1002/14651858.CD006015.pub3. PMID 20927745.
^ Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792.
^ Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–30. doi:10.1007/s40257-014-0077-5. PMID 24848508. S2CID 31245042.
^ Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792. In studies addressing reversibility, most of these patients have resolution of sexual adverse effects after discontinuation of finasteride, and many have improvement of adverse effects over time with continued finasteride use. However, some studies CAPSULE SUMMARY d Prescription medications are a common cause of sexual dysfunction. Possible sexual adverse effects should be discussed with men using these medications. d We identified evidence for sexual adverse effects in patients taking 11 systemic dermatologic medications. Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.
^ Traish AM (January 2020). "Post-finasteride syndrome: a surmountable challenge for clinicians". Fertility and Sterility. 113 (1): 21–50. doi:10.1016/j.fertnstert.2019.11.030. PMID 32033719.
^ Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–30. doi:10.1007/s40257-014-0077-5. PMID 24848508. S2CID 31245042.
^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 483. ISBN 978-3-527-60749-5.
^ "Proscar- finasteride tablet, film coated". DailyMed. 15 November 2019. Retrieved 16 September 2020.
^ "Propecia- finasteride tablet, film coated". DailyMed. 15 November 2019. Retrieved 16 September 2020.
^ Sudduth SL, Koronkowski MJ (1993). "Finasteride: the first 5α-reductase inhibitor". Pharmacotherapy. 13 (4): 309–25, discussion 325–9. doi:10.1002/j.1875-9114.1993.tb02739.x (inactive 22 December 2020). PMID 7689728.{{cite journal}}: CS1 maint: DOI inactive as of کانوونی یەکەم 2020 (link)

[AHFS2019-1] ئ ^ا ^ب "Finasteride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 5 March 2019.

[Blume-PeytaviWhiting2008-2] Blume-Peytavi, Ulrike; Whiting, David A.; Trüeb, Ralph M. (26 June 2008). Hair Growth and Disorders. Springer Science & Business Media. p. 369. ISBN 978-3-540-46911-7.

[TranssexualMgmnt2012-3] Knezevich EL, Viereck LK, Drincic AT (January 2012). "Medical management of adult transsexual persons". Pharmacotherapy. 32 (1): 54–66. doi:10.1002/PHAR.1006. PMID 22392828. S2CID 12853220.

[4] Ferri, Fred F. (2014). Ferri's Clinical Advisor 2015 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 580. ISBN 978-0-323-08430-7.

[Cochrane20102-5] Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ (October 2010). "Finasteride for benign prostatic hyperplasia". The Cochrane Database of Systematic Reviews (10): CD006015. doi:10.1002/14651858.CD006015.pub3. PMID 20927745.

[6] Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792.

[2014AArev-7] Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–30. doi:10.1007/s40257-014-0077-5. PMID 24848508. S2CID 31245042.

[Zax2019-8] Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792. In studies addressing reversibility, most of these patients have resolution of sexual adverse effects after discontinuation of finasteride, and many have improvement of adverse effects over time with continued finasteride use. However, some studies CAPSULE SUMMARY d Prescription medications are a common cause of sexual dysfunction. Possible sexual adverse effects should be discussed with men using these medications. d We identified evidence for sexual adverse effects in patients taking 11 systemic dermatologic medications. Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.

[Tra2020-9] Traish AM (January 2020). "Post-finasteride syndrome: a surmountable challenge for clinicians". Fertility and Sterility. 113 (1): 21–50. doi:10.1016/j.fertnstert.2019.11.030. PMID 32033719.

[2014AArev2-10] Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–30. doi:10.1007/s40257-014-0077-5. PMID 24848508. S2CID 31245042.

[Fis2006-11] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 483. ISBN 978-3-527-60749-5.

[Proscar_FDA_label-12] "Proscar- finasteride tablet, film coated". DailyMed. 15 November 2019. Retrieved 16 September 2020.

[Propecia_FDA_label-13] "Propecia- finasteride tablet, film coated". DailyMed. 15 November 2019. Retrieved 16 September 2020.

[pmid7689728-14] Sudduth SL, Koronkowski MJ (1993). "Finasteride: the first 5α-reductase inhibitor". Pharmacotherapy. 13 (4): 309–25, discussion 325–9. doi:10.1002/j.1875-9114.1993.tb02739.x (inactive 22 December 2020). PMID 7689728.{{cite journal}}: CS1 maint: DOI inactive as of کانوونی یەکەم 2020 (link)

[١]

[٢]

[٣]

[٤]

[٥]

[٦]

[٧]

[٨]

[٩]

[١٠]

[١١]

[١٢]

[١٣]

[١٤]